Pricing Log in Create free account

Halozyme Therapeutics, Inc. (HALO) vs Summit Therapeutics PLC (SMMT)

Halozyme Therapeutics, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $13.8B against $12.3B — 1.1× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 34.6×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against −61.0%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 0.00%) and the higher return on invested capital (18.1% vs 0.00%). Across the 19 metrics below, Halozyme Therapeutics, Inc. leads on 14 and Summit Therapeutics PLC on 5.

Valuation

Metric HALO SMMT Biotechnology median
P/E 34.61 n/m 8.50
P/S 8.59 16,148.72 9.71
P/B 99.54 18.07 2.13
Price to free cash flow 17.72 n/m 20.82
EV/EBITDA 22.53 n/m 0.64
EV/Sales 9.74 15,310.43 9.21
Earnings yield 2.89% (7.66%) (33.15%)
Free cash flow yield 5.64% (4.04%) (25.50%)

Profitability

Metric HALO SMMT Biotechnology median
Gross margin 82.42% 100.00% 65.16%
Operating margin 35.90% 0.00% 0.00%
Net margin 24.86% 0.00% 0.00%
Free cash flow margin 48.46% 0.00% 0.00%
Return on equity 173.67% (192.50%) (56.36%)
Return on assets 17.86% (159.09%) (48.04%)
Return on invested capital 18.13% 0.00% 0.00%

Growth

Metric HALO SMMT Biotechnology median
Revenue growth (TTM) 41.15% (61.03%) 6.02%
EPS growth (last fiscal year) (25.36%) (364.52%) 30.26%
Revenue growth, 5-year CAGR 39.16% (46.49%) 9.41%
Net income growth, 5-year CAGR 19.68% 0.00% 0.00%

Health

Metric HALO SMMT Biotechnology median
Debt to equity 14.95 0.00 0.00
Current ratio 2.71 6.96 4.72
Net debt to EBITDA 3.56 0.65 0.96

Dividend

Metric HALO SMMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric HALO SMMT Biotechnology median
Market cap 13.79b 12.26b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack